This is an old revision of the document!
Oragenics
Affiliations
Acquisitions
In May 2020, Oragenics acquired Noachis Terra to “develop and commercialize TerraCoV2, a vaccine candidate which could provide specific immunity from the novel coronavirus (SARS-CoV-2).1)
COVID-19
Oragenics is developing an intranasal COVID-19 vaccine product with BioDextris.2)
1)
Abraham, J. (2020, May 4). ..Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein” :: Oragenics, Inc. (OGEN)… Oragenics. https://ir.oragenics.com/press-releases/detail/104/oragenics-acquires-noachis-terra-inc-to-develop-its
2)
Sullivan, M., & Golodetz, K. (2021, March 9). Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine. Business Wire; Berkshire Hathaway. https://archive.ph/QrWCj